Valiant LaboratoriesNSE:VALIANTLAB -0.06%51 Gross Margin % is 21.58% as of Mar. 2026, which is 36% above its 10-year median of 15.86. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Valiant Laboratories ranks worse than 92.22% on this metric.
NSE:VALIANTLAB's Gross Margin % is ranked worse than 92.22% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs NSE:VALIANTLAB: 16.98
Valiant Laboratories had a gross margin of 21.58% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Valiant Laboratories was -15.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Valiant Laboratories had a gross margin of 21.58% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Valiant Laboratories Gross Margin % Related Terms
Valiant Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Valiant Laboratories (NSE:VALIANTLAB) has a Gross Margin % of 21.58% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Valiant Laboratories and its competitors. This is 36% above median its historical median of 15.86. Over the past decade, Valiant Laboratories' Gross Margin % has ranged from 3.04 to 32.02. According to the industry distribution chart, Valiant Laboratories ranks #865 out of 938 companies in the Drug Manufacturers industry, placing it in the top 92.2%.
Is Valiant Laboratories' Gross Margin % too high?
Valiant Laboratories' current Gross Margin % of 21.58% is 36% above median its 10-year median of 15.86. Over the past 10 years, this metric has ranged from a low of 3.04 to a high of 32.02. The Drug Manufacturers industry median Gross Margin % is 48.44. Valiant Laboratories' value of 21.58% is 55.5% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #865 out of 938 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #865 out of 938 companies for Gross Margin %. This places Valiant Laboratories in the lower half of its industry. The industry median Gross Margin % is 48.44. Valiant Laboratories' value of 21.58% is 55.5% below this benchmark. Historically, Valiant Laboratories' own Gross Margin % has ranged from 3.04 to 32.02 over the past decade. While the company's 10-year median is 15.86 vs. the industry median of 48.44, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Gross Margin % of 21.58% is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Gross Margin % is 21.58%, which is 36% above median its own 10-year median of 15.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Gross Margin % is 21.58%, which is 36% above median its 10-year median of 15.86 and 55.5% below the Drug Manufacturers industry median of 48.44. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Gross Margin % is 21.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Gross Margin %: 21.58% (36% above median its 10-year median of 15.86)
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
Industry Position: 55.5% below the Drug Manufacturers median (#865 of 938)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
